Peritoneal Cancer Market Outlook 2025-2035: The 7 major Peritoneal Cancer Market are expected to exhibit a CAGR of 18.7% during 2025-2035. The peritoneal cancer market is growing, as people become ...

The benefits of HIPEC include improved local control of cancer, reduced recurrence rates, and enhanced survival outcomes for ...

Background: Gastric cancer (GC) still represents the third leading cause of cancer-related death worldwide. Peritoneal relapse (PR) is the most frequent metastasis occurring among patients with ...

The guideline authors used data from 61 studies to provide recommendations on the use of neoadjuvant chemotherapy in patients with newly diagnosed, stage III-IV epithelial ovarian, fallopian tube, or ...

Nesuparib is under clinical development by Onconic Therapeutics and currently in Phase II for Peritoneal Cancer. According to GlobalData, Phase II drugs for Peritoneal Cancer have a 37% phase ...

More than half of all patients with colorectal cancer (CRC) develop distant metastasis and, depending on the local stage of the primary tumor, up to 48% of patients present peritoneal carcinomatosis ...

Development of new therapeutic strategies to enhance the effectiveness of irinotecan in colorectal cancer treatment.

Real-world safety of trastuzumab deruxtecan with gastric cancer: All-patient post-marketing surveillance study in Japan. This is an ASCO Meeting Abstract from the 2025 ASCO Gastrointestinal Cancers ...

Adding intraperitoneal paclitaxel to intravenous paclitaxel and oral S-1 improved survival in patients with gastric cancer and peritoneal metastasis.

Zentalis Pharmaceuticals, Inc.’s ZNTL share price has dipped by 11.11%, which has investors questioning if this is right time ...

A three-day conference on Peritoneal Surface malignancy was held at Thangam Hospital and Cancer Center, Namakkal. Peritoneal Surface malignancy (PSM) is a super special branch dealing with cancers of ...